224 related articles for article (PubMed ID: 10022244)
1. The CD95(APO-1/Fas)/CD95L system.
Krammer PH
Toxicol Lett; 1998 Dec; 102-103():131-7. PubMed ID: 10022244
[TBL] [Abstract][Full Text] [Related]
2. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system.
Li-Weber M; Krammer PH
Semin Immunol; 2003 Jun; 15(3):145-57. PubMed ID: 14563113
[TBL] [Abstract][Full Text] [Related]
3. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L.
Aragane Y; Kulms D; Metze D; Wilkes G; Pöppelmann B; Luger TA; Schwarz T
J Cell Biol; 1998 Jan; 140(1):171-82. PubMed ID: 9425165
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma augments CD95(APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis.
Li JH; Kluger MS; Madge LA; Zheng L; Bothwell AL; Pober JS
Am J Pathol; 2002 Oct; 161(4):1485-95. PubMed ID: 12368221
[TBL] [Abstract][Full Text] [Related]
5. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Fulda S; Strauss G; Meyer E; Debatin KM
Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
[TBL] [Abstract][Full Text] [Related]
6. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
7. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis.
Sträter J; Wellisch I; Riedl S; Walczak H; Koretz K; Tandara A; Krammer PH; Möller P
Gastroenterology; 1997 Jul; 113(1):160-7. PubMed ID: 9207274
[TBL] [Abstract][Full Text] [Related]
8. Defining CD95 as a tumor suppressor gene.
Müschen M; Warskulat U; Beckmann MW
J Mol Med (Berl); 2000; 78(6):312-25. PubMed ID: 11001528
[TBL] [Abstract][Full Text] [Related]
9. Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.
Debatin KM; Beltinger C; Böhler T; Fellenberg J; Friesen C; Fulda S; Herr I; Los M; Scheuerpflug C; Sieverts H; Stahnke K
Biochem Soc Trans; 1997 May; 25(2):405-10. PubMed ID: 9191126
[No Abstract] [Full Text] [Related]
10. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Galle PR; Hofmann WJ; Walczak H; Schaller H; Otto G; Stremmel W; Krammer PH; Runkel L
J Exp Med; 1995 Nov; 182(5):1223-30. PubMed ID: 7595193
[TBL] [Abstract][Full Text] [Related]
11. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
12. Role of the CD95/CD95 ligand system in glucocorticoid-induced monocyte apoptosis.
Schmidt M; Lügering N; Lügering A; Pauels HG; Schulze-Osthoff K; Domschke W; Kucharzik T
J Immunol; 2001 Jan; 166(2):1344-51. PubMed ID: 11145719
[TBL] [Abstract][Full Text] [Related]
13. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.
Maher S; Toomey D; Condron C; Bouchier-Hayes D
Immunol Cell Biol; 2002 Apr; 80(2):131-7. PubMed ID: 11940113
[TBL] [Abstract][Full Text] [Related]
14. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
15. Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand.
Müller KP; Mariani SM; Matiba B; Kyewski B; Krammer PH
Eur J Immunol; 1995 Oct; 25(10):2996-9. PubMed ID: 7589104
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
[TBL] [Abstract][Full Text] [Related]
17. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?
Strand S; Hofmann WJ; Hug H; Müller M; Otto G; Strand D; Mariani SM; Stremmel W; Krammer PH; Galle PR
Nat Med; 1996 Dec; 2(12):1361-6. PubMed ID: 8946836
[TBL] [Abstract][Full Text] [Related]
19. CD95/CD95L interactions and their role in autoimmunity.
Ricci-Vitiani L; Conticello C; Zeuner A; De Maria R
Apoptosis; 2000 Nov; 5(5):419-24. PubMed ID: 11256883
[TBL] [Abstract][Full Text] [Related]
20. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
